Advanced search
Start date

Effects of sulfiredoxin silencing on chemosentivity of prostate cancer cells PC3 and DU145

Grant number: 21/12929-0
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): December 01, 2021
Effective date (End): November 30, 2022
Field of knowledge:Biological Sciences - Morphology - Cytology and Cell Biology
Principal researcher:Sérgio Luis Felisbino
Grantee:Micheli Canuto de Lima
Home Institution: Instituto de Biociências (IBB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil


Prostate cancer (CaP) is the second most prevalent cancer in men in Brazil and worldwide. For localized tumors, available treatments have allowed a high rate of cure and survival with the disease. For metastatic tumors, cure rates decrease considerably but can be controlled initially with anti-androgenic therapies. However, most metastatic tumors evolve to their lethal form that is resistant to androgen deprivation, known as metastatic and castration-resistant prostate cancer. For these tumors, treatment with chemotherapy is one of the options, such as with docetaxel, but such treatment has the disadvantages of undesirable side effects and a significant rate of tumor cell resistance. After resistance to docetaxel, the patient's life expectancy significantly decreases, leading to treatment failure. Recent studies suggest that the action of the antioxidant enzyme Sulfiredoxin, overexpressed in more advanced stages of CaP, helps in its chemoresistance, making it more resistant to the oxidative actions of chemotherapy and radiotherapy treatments. Therefore, this study aims to evaluate the chemosensitivity of PC3 and DU145 tumor cells after sulfiredoxin precursor SRXN1 gene silencing, in order to assess its potential to be used as an adjuvant in docetaxel treatment in the clinic. The silencing will be performed through siRNA against the SRXN1 gene, while cell viability and its chemosensitivity will be evaluated by MTT assays. Additional assays that assess the invasive and migratory behavior of these tumor cells (Wound Healing and assays with insert and matrigel) will also be performed. In this study, we hypothesize that SRXN1 silencing makes tumor cells more sensitive to the action of docetaxel.(AU

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list by writing to: